Apellis Report US FDA Approval Of EMPAVELI Injector, A Device To Streamline Self-Administration
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals has received US FDA approval for its EMPAVELI Injector, a device designed to streamline self-administration of EMPAVELI (pegcetacoplan), a treatment for adults with paroxysmal nocturnal hemoglobinuria (PNH).
October 02, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA approval of Apellis' EMPAVELI Injector could potentially increase the usage of EMPAVELI, thereby potentially boosting the company's revenues.
The FDA approval of the EMPAVELI Injector is a positive development for Apellis. The device is designed to streamline the self-administration of EMPAVELI, which could lead to increased usage of the drug. This could potentially result in increased revenues for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100